Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
16 10월 2023 - 8:00PM
Business Wire
— Demonstrated preclinical efficacy of LSD1
inhibitor in primary AML samples —
— Initial data supporting combination potential
of LSD1 inhibitor with AML standard of care therapies —
— Tumour growth inhibition through MALT1 in
monotherapy and combination while lowering bilirubin toxicity risk
—
Exscientia plc (Nasdaq: EXAI) today announced two abstracts to
be presented at the upcoming European Society for Medical Oncology
(ESMO) Congress 2023 from October 20-24, 2023 in Madrid, Spain.
“We are excited to share new preclinical data on our
precision-designed LSD1 and MALT1 inhibitors, which we introduced
to our oncology pipeline earlier this year,” said Professor Andrew
Hopkins FRS FMedSci, founder and Chief Executive Officer of
Exscientia. “We believe these compounds bear strong potential for
differentiation, patient benefit and value creation. This data
underlines how Exscientia can bring together AI design and novel
translational research capabilities to create better quality drug
candidates. This also allows us to systematically identify those
patient populations who have the most potential benefit well before
we start clinical trials.”
Both ESMO posters will be available on the Exscientia website
from their time of presentation.
Poster Presentations
Title: Determining anti-cancer efficacy of a reversible
LSD1 inhibitor, EXS74539, in primary AML tissues with limited
thrombocytopenic effects Session Title: Translational
research (agnostic) Abstract Number: 2289P Date/Time:
Saturday, October 21 / 12:00 PM – 1:00 PM CEST
- ‘539 is a novel, potent, selective and reversible LSD1
inhibitor under preclinical investigation as a monotherapy or in
combination with standard of care for oncology and haematology
indications including acute myeloid leukaemia (AML) and small cell
lung cancer (SCLC)
- Leveraging primary human material and Exscientia’s proprietary
precision medicine platform, the Company confirmed ‘539’s general
efficacy, demonstrating that ‘539 induces AML cell differentiation
marker expression when used on primary AML patient tissue ex
vivo
- Combination data with first line AML and targeted therapies
will be presented
Title: Characterisation of EXS73565, a potent and
selective MALT1 inhibitor with low drug-drug interaction risk and
potential in lymphoma Session Title: Haematological
malignancies Abstract Number: 832P Date/Time: Monday,
October 23 / 12:00 PM – 1:00 PM CEST
- Exscientia utilised generative design, machine learning and
molecular dynamics approaches to precision-design ‘565, a potent
and selective allosteric MALT1 inhibitor with a differentiated
profile exhibiting low drug-drug interaction and hyperbilirubinemia
risk
- Preclinically, ‘565 exposure resulted in limited inhibition of
UGT1A1, an enzyme involved in bilirubin metabolism. This approach
has the potential to offer safety benefits compared to other
clinical stage MALT1 inhibitors which carry a high UGT1A1
inhibition and hyperbilirubinemia risk
- Significant tumour growth inhibition was observed for ‘565 in
vivo in activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)
xenograft models. Significant synergistic effects were observed for
combination ‘565 and the BTK inhibitor ibrutinib in a xenograft
model with low sensitivity to either single agent
- Overall, the profile of ‘565 offers the potential for clinical
exploration of MALT1 inhibition as a monotherapy and/or in
combination with other targeted agents in haematological
malignancies
About Exscientia
Exscientia is an AI-driven precision medicine company committed
to discovering, designing and developing the best possible drugs in
the fastest and most effective manner. Exscientia developed the
first-ever functional precision oncology platform to successfully
guide treatment selection and improve patient outcomes in a
prospective interventional clinical study, as well as to progress
AI-designed small molecules into the clinical setting. Our internal
pipeline is focused on leveraging our precision medicine platform
in oncology, while our partnered pipeline broadens our approach to
other therapeutic areas. By pioneering a new approach to medicine
creation, we believe the best ideas of science can rapidly become
the best medicines for patients.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, including statements with
regard to Exscientia’s expectations regarding its Board of
Directors. Words such as “anticipates,” "believes," “expects,”
"intends," "projects," "anticipates," and "future" or similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are subject to the uncertainties
inherent in predicting future results and conditions and no
assurance can be given that the drug discovery and precision
medicine platforms discussed above will be successful in optimising
drug candidates for specific patient populations. The success of
Exscientia’s platforms is subject to numerous factors, many of
which are beyond the control of Exscientia, including, without
limitation, the ability of Exscientia to design clinical trials
that are cleared by the FDA and of healthcare providers to collect
viable patient tissue samples. Exscientia undertakes no obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as may be required by law.
Visit us at https://www.exscientia.ai or follow us on X/Twitter
@exscientiaAI.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231016372855/en/
Investor Relations Contact: Sara Sherman
investors@exscientia.ai Media Contact: Oliver Stohlmann
media@exscientia.ai
Exscientia (NASDAQ:EXAI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Exscientia (NASDAQ:EXAI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024